SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-034881-2023-05-03T12:45:43+01:00",
    "date": "2023-05-03T12:45:43+01:00",
    "ocid": "ocds-h6vhtk-034881",
    "initiationType": "tender",
    "tender": {
        "id": "CBRN/00272",
        "legalBasis": {
            "id": "32009L0081",
            "scheme": "CELEX"
        },
        "title": "SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "33651520",
            "description": "Immunoglobulins"
        },
        "mainProcurementCategory": "goods",
        "description": "The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), has placed a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 3 years. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.",
        "lots": [
            {
                "id": "1",
                "description": "The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of PS20M+. This is necessary to ensure maintenance of the capability with an acceptable stockholding level. Due to the estimated contract value and on the basis that it is to be placed directly with Emergent Biosolutions Canada Inc, the contract will be a Qualifying Defence Contract (QDC) and shall comply with the Single Source Contract Regulations (SSCR) 2014. It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where \"Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons\". Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT(r)) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence. Additional information: Due to the limitations of the character limit at II 2.4) Description -- it is not possible to enter the full details of the single source justification, for full details of the reasoning, please email Tamika.Kelly116@mod.gov.uk so that it can be forwarded to you.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "type": "price",
                            "name": "Lowest price"
                        }
                    ]
                },
                "hasOptions": true,
                "options": {
                    "description": "5 Optional Years"
                }
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "CA"
                    }
                ],
                "relatedLot": "1"
            },
            {
                "id": "0",
                "deliveryAddresses": [
                    {
                        "region": "CA"
                    }
                ]
            }
        ],
        "procurementMethod": "limited",
        "procurementMethodDetails": "Negotiated without publication of a contract notice",
        "procurementMethodRationaleClassifications": [
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_PROC_NEGOTIATED_PRIOR_CALL_COMPETITION",
                "description": "No tenders or no suitable tenders/requests to participate in response to negotiated procedure with prior publication of a contract notice"
            },
            {
                "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL",
                "id": "D_TECHNICAL",
                "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons"
            }
        ],
        "procurementMethodRationale": "It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where \"Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons\". Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT(r)) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.",
        "additionalClassifications": [
            {
                "scheme": "TED_TYPE_SUPPLIES_CONTRACT",
                "id": "PURCHASE",
                "description": "Purchase"
            }
        ],
        "awardCriteria": {
            "criteria": [
                {
                    "type": "price",
                    "name": "Lowest price"
                }
            ]
        }
    },
    "awards": [
        {
            "id": "016860-2022-CBRN/00272-1",
            "relatedLots": [
                "1"
            ],
            "title": "SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)",
            "status": "active",
            "hasSubcontracting": true,
            "suppliers": [
                {
                    "id": "GB-FTS-56162",
                    "name": "Emergent Biosolutions Canada Inc"
                }
            ]
        },
        {
            "id": "012644-2023-CBRN/00272-1",
            "status": "active",
            "hasSubcontracting": false,
            "suppliers": [
                {
                    "id": "GB-FTS-81777",
                    "name": "Emergent BioSolutions Canada Inc."
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-5483",
            "name": "Ministry of Defence",
            "identifier": {
                "legalName": "Ministry of Defence"
            },
            "address": {
                "locality": "Bristol",
                "region": "UK",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "Tamika.Kelly116@mod.gov.uk"
            },
            "roles": [
                "reviewBody"
            ],
            "details": {
                "url": "https://www.gov.uk/",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "02",
                        "description": "Defence"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-56162",
            "name": "Emergent Biosolutions Canada Inc",
            "identifier": {
                "legalName": "Emergent Biosolutions Canada Inc"
            },
            "address": {
                "locality": "Winnipeg",
                "region": "CA",
                "countryName": "Canada"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "large"
            }
        },
        {
            "id": "GB-FTS-81776",
            "name": "Ministry of Defence",
            "identifier": {
                "legalName": "Ministry of Defence"
            },
            "address": {
                "streetAddress": "Chemical Biological Radiological Nuclear (CBRN) Delivery Team, Yew 3A, #1342 MOD Abbey Wood",
                "locality": "Bristol",
                "postalCode": "BS34 8JH",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Attn: Lewis Dale",
                "email": "dale.lewis176@mod.gov.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.gov.uk/",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "MINISTRY",
                        "description": "Ministry or any other national or federal authority, including their regional or local subdivisions"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "02",
                        "description": "Defence"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-81777",
            "name": "Emergent BioSolutions Canada Inc.",
            "identifier": {
                "legalName": "Emergent BioSolutions Canada Inc."
            },
            "address": {
                "streetAddress": "155 Innovation Dr",
                "locality": "Winnipeg",
                "postalCode": "R3T 5Y3",
                "countryName": "Canada"
            },
            "roles": [
                "supplier"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-81776",
        "name": "Ministry of Defence"
    },
    "contracts": [
        {
            "id": "016860-2022-CBRN/00272-1",
            "awardID": "016860-2022-CBRN/00272-1",
            "title": "SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)",
            "status": "active",
            "value": {
                "amount": 22000000,
                "currency": "GBP"
            },
            "dateSigned": "2022-06-07T00:00:00+01:00"
        },
        {
            "id": "012644-2023-CBRN/00272-1",
            "awardID": "012644-2023-CBRN/00272-1",
            "status": "active",
            "value": {
                "amount": 12955456.35,
                "currency": "GBP"
            },
            "period": {
                "durationInDays": 1095
            },
            "dateSigned": "2023-04-13T00:00:00+01:00"
        }
    ],
    "language": "en",
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "value": 1
            },
            {
                "id": "2",
                "measure": "electronicBids",
                "value": 1
            }
        ]
    }
}